Seeding Drug Discovery
Seeding Drug Discovery collaborative projects can be formed where an academic partner brings a 'validated' project forward for collaboration. Such collaborations may need to prove the tractability of the hypothesis or develop existing lead molecules. Eisai can assist with Hit and/or Lead finding activities as well as subsequent advice and assistance in Hit or Lead Optimisation projects.
An example of an existing Seeding Drug Discovery alliance is our collaboration with the Johns Hopkins School of Medicine Brain Science Institute (JHBSi). This partnership is expected to provide new opportunities to deliver innovative drug treatments by combining JHBSi’s translational research strengths with Eisai’s neurology drug discovery expertise. Using an Open Innovation research model JHBSi has assumed a leading role in conducting drug discovery research, with a shared vision of identifying clinically-viable drugs. JHBSi scientists therefore contribute not only new neurodegenerative disease targets and biological expertise, but also in-house drug discovery capability (including medicinal chemistry). In return Eisai provide access to a proprietary compound library, assay development and screening expertise. To date this research collaboration has produced two drug discovery research programs which have completed a high-throughput screen using Eisai’s compound collection. Other potential projects are in the pipeline.
The JHBSi was created to fuel novel, collaborative research among Johns Hopkins’ more than 500 basic and clinical neuroscientists. The collaboration operates as part of the JHBSi’s Neuro Translational Program, launched in 2009, whose mission is to explore innovative ways to accelerate promising drug discovery and translation by leveraging the basic research and clinical expertise of the Johns Hopkins University neuroscience community. Eisai has identified neurology as a therapeutic area of focus and has entered into this partnership as part of its commitment to uncovering the causes of neurodegenerative disease and to identify new opportunities for therapeutic intervention.